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The DNA sequence and transcription pattern of human cytomegalovirus early gene UL84 were analyzed.
This gene was mapped within a 2.6-kb PstI fragment located between 0.534 and 0.545 map unit of the large
unique segment of the human cytomegalovirus genome, which is adjacent to the pp65 and pp71 genes. A 2.0-kb
mRNA was transcribed from this region in the same leftward direction as the mRNAs of the pp65 and pp7l
genes. The message was first detected at 2.5 h postinfection and reached a maximal level between 72 and 96 h
postinfection. The nucleotide sequences of the 2.6-kb PstI genomic DNA fragment and the cDNA derived from
this region were determined. The resulting data revealed a polyadenylation signal (AATAAA) located 14
nucleotides upstream from the poly(A) tail of the cDNA and a 1,761-bp open reading frame capable of encoding
a 65-kDa polypeptide. A potential leucine zipper was found in the N-terminal half of the peptide molecule
between amino acids 114 and 135. In addition, a different periodic leucine repeat with leucine at every eighth
position was found between amino acids 325 and 373. The transcriptional initiation site of this early gene was
determined by primer extension analysis. A putative TATA box (TATTTAA) located 24 bp upstream of the cap
site and several inverted repeats were found in the region further upstream of the TATA box. To test whether
the open reading frame of this cDNA encodes a virus-specific protein, the cDNA was overexpressed in
Escherichia coli as a fusion protein used to generate antibodies in rabbits. A protein with a molecular size of
65 kDa was detected in the infected-cell extracts harvested at 6 to 72 h postinfection, but not in purified virions,
using immunoblot analysis. Both nuclear and cytoplasmic fluorescences were found at late stages of virus
infection. From the results obtained, we postulate that UL84 may be a stable, virus-specific, nonstructural
protein capable of forming a homo- or heterodimeric molecule.
Human cytomegalovirus (CMV) is a linear double-strand
DNA virus with a genome of approximately 150 x 106 Da or
240 kb. The genomic complexity ofCMV makes it one of the
largest animal DNA viruses discovered to date. This virus is
associated with many clinical manifestations, ranging from
developmental abnormality to fatal CMV pneumonitis in
organ transplant and AIDS patients. The latency, reactiva-
tion, and oncogenic potentials of human CMV are compara-
ble to those of other herpes group viruses. Human CMV
gene expression is regulated in a cascade manner in permis-
sive cells. Viral genes have been classified into three major
groups based on their temporal order and the functional
requirements for their expression (24, 49, 50). The first group
of genes, designated immediate-early (IE) or alpha genes, is
expressed within 2 to 4 h after infection without prior viral
protein synthesis. These genes encode predominantly regu-
latory proteins with transactivating activities (1, 10, 12, 13,
37, 41, 42, 44-48). The next group of genes, designated early
or beta genes, requires prior viral IE protein synthesis. This
group of genes encodes predominantly nonstructural pro-
teins, many of which are enzymes involved in viral DNA
replication (2, 3, 6, 8, 11, 21, 41). With the onset of viral
DNA replication, the expression of a third group of genes is
initiated. This group of genes consists of late or gamma
genes encoding virus-specific structural proteins (15, 16, 22,
23, 26-31, 36).
A number ofCMV early genes have recently been studied,
and viral IE proteins were commonly found to be needed for
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the activation of early promoters (2, 9, 16, 18, 19, 38).
Analyses of sequences responsible for transactivation by IE
proteins suggest that both direct and inverted repeats within
promoter regions of these early genes might be involved in
the regulation of early gene expression. However, no signif-
icant homology or consensus sequence could be detected
among the repeat regions of various CMV early promoter
sequences. The promoter region of a 2.2-kb RNA tran-
scribed from the EcoRI fragments R and d contains two
9-base direct repeats, GCGGAAAGG and ACGTTGTTT
(43). A palindromic octamer sequence, TCACGTGA, that is
similar to the consensus binding site of MLTF/USF
(CCACGTGA) of the promoter of adenovirus major late
genes was found located between -112 and -105 of the
promoter of a 2.7-kb RNA expressed from the EcoRI frag-
ments 0 and W (18, 19). Likewise, the regulatory region of
pp65 has an octameric sequence, ATTCGGG (9). In the case
of the UL84 early gene, four pairs of inverted repeat
sequences and a cyclic AMP (cAMP) response element were
found within the promoter-enhancer sequences of the UL84
gene.
The UL84 gene is located within EcoRI fragment A,
mapped within 0.534 to 0.545 map unit of the large unique
segment of the human CMV genome. It is adjacent to the
region encoding tegument proteins pp65 and pp7l, as de-
scribed by Ruger et al. (37). This gene was named UL84 in
conformity with the nomenclature of Chee et al. (4). Given
the unique promoter-enhancer sequence of UL84 and the
extremely early appearance of its transcriptional and trans-
lational products, as compared with other CMV early genes,
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we performed detailed DNA sequence, transcription, and
translation analyses of this unique gene.
MATERIALS AND METHODS
Virus and cells. Human embryonic lung (HEL) fibroblasts
(ATCC HEL 229, passages 16 to 24) were used for the
propagation of virus and biochemical studies. HEL cells
were cultured in Eagle's minimal essential medium supple-
mented with 10% fetal calf serum. The Towne strain of
human CMV was propagated in HEL cells by standard
methods. All experiments were conducted at multiplicities of
1 to 2 PFU per cell. Extracellular virions were purified by
sucrose and CsCl gradient centrifugation as described before
(17).
Construction and screening of cDNA libraries. Total and
cytoplasmic RNAs were isolated from human CMV-infected
HEL cells at 72 h postinfection by the standard method (33).
Polyadenylated RNAs were selected by oligo(dT)-cellulose
column chromatography. Double-stranded cDNA was syn-
thesized from poly(A) RNA by using oligo(dT) as a primer.
The cDNA synthesized was methylated with EcoRI methyl-
ase prior to ligation with EcoRI linkers. After size fraction-
ation through a Sepharose 48 column, cDNAs larger than
0.5 kb were inserted into the EcoRI sites of lambda gtll and
packaged in vitro, using packaging extracts obtained from
Promega (Madison, Wis.). Escherichia coli Y1088 cells were
used as hosts to amplify the recombinant phage. Two
libraries which contain independent recombinants, 1.5 x 106
and 2 x 106, were constructed from total and cytoplasmic
mRNAs, respectively.
Approximately 4 x 104 recombinant phages from the total
mRNA library were screened with a 32P-labeled CMV ge-
nomic DNA subclone, pHD1013-211, containing the pp65
and pp7l genes and the upstream region of the pp65 gene as
described by Huynh et al. (14a). Positive plaques obtained
from the first high-density screening were further purified
through three successive rounds of DNA hybridization
screening with low plaque densities. Recombinant phage
DNA was prepared from plate lysates, digested with EcoRI,
and then subcloned directly into bacteriophage M13mpl9 at
the EcoRI site. Another 4 x 104 recombinant phages from a
cytoplasmic mRNA library were screened with the cDNA
probe.
DNA cloning and Southern hybridization. Plasmid pHD1,
containing the EcoRI A fragment of the CMV genome, and
pHD1013-211, containing a 6.5-kb BamHI fragment from
pHD1, were constructed by Davis and Huang (7). pHD1 was
digested with EcoRI, and the 27-kb EcoRI fragment A was
separated by agarose gel electrophoresis. This fragment was
digested with BamHI and PstI and transferred to nitrocellu-
lose, and Southern hybridization was performed by standard
methods (32). Prehybridization was carried out in a mixture
of 25 mM KPO4 (pH 7.4), 6x SSC (0.9 M NaCl, 0.09 M
sodium citrate), 5x Denhardt's solution (0.1% Ficoll, 0.1%
polyvinylpyrrolidone, 0.1% bovine serum albumin), 50 ,ug of
salmon sperm DNA per ml, and 0.1% sodium dodecyl sulfate
(SDS) at 42°C for 4 h. After prehybridization, 32P-labeled
cDNA (2 x 105 cpm/ml) in prehybridization buffer was
added. Following hybridization, filters were washed twice in
lx SSC-0.1% SDS and twice in 0.25x SSC-0.1% SDS at
room temperature for 15 min and then once in 0.25 x
SSC-0.1% SDS at 600C for 1 h. A 2.6-kb PstI fragment which
hybridized with the cDNA probe, designated pHD1A, was
recovered from an agarose gel and subcloned into bacterio-
phage M13mpl9.
DNA sequencing and computer analysis. cDNA and ge-
nomic DNA sequencing was performed by the chain termi-
nation method (39), using the Sequenase kit (U.S. Biochem-
ical Corp.) and Sequentide (NEG-034N; New England
Nuclear). Single- and double-stranded templates were ob-
tained from subclones constructed with appropriate restric-
tion enzymes, including BamHI, HindIII, Sall, PstI, and
SphI. All sequences were obtained and confirmed by using
data from both directions. Eight synthetic oligonucleotides
were applied as sequencing primers to resolve the sequence
gaps and to confirm the strand inconsistencies. Open reading
frame (ORF) analyses were carried out with the DNA
Inspector II (Textco, West Lebanon, N.H.). Two-dimen-
sional protein structure as well as hydrophilicity and hydro-
phobicity profiles of the deduced peptide were determined
by using a software package provided by the Genetics
Computer Group (University of Wisconsin, Madison).
Northern (RNA) hybridization. Total RNAs were prepared
from mock- and CMV-infected HEL cells by the method
described above. To prepare authentic IE RNA, cells were
treated with 50 pRg of cycloheximide (CH) per ml for 1 h
before infection and then infected with virus in the presence
of CH. Cells were harvested at 2.5 h postinfection. Total
RNA (8 ,ug per well) was subjected to electrophoresis on a
1.2% agarose gel containing 6% formaldehyde and then
transferred to nitrocellulose. The resulting filter was prehy-
bridized at 42°C for 24 h and then hybridized with a 32p_
labeled cDNA probe at 42°C for 14 h as described above for
Southern hybridization. After washing, the hybridized filter
was autoradiographed overnight at -70°C.
The same blot was stripped of the 32P-labeled cDNA probe
by boiling in TE buffer (10 mM Tris-HCI [pH 7.5], 1 mM
EDTA) for 15 min and reprobed with a 32P-labeled cDNA of
the gene for 28S rRNA.
Primer extension. Primer extension experiments were per-
formed by the method of Kingston (34), with minor modifi-
cation. A 20-bp oligonucleotide, 5'-TGCACCCGAGGCTGA
CGGAT-3', was synthesized on an Applied Biosystems
synthesizer and end labeled with [_y-32P]ATP by T4 polynu-
cleotide kinase. Six micrograms of total RNA and 2 x 104
cpm of primer were mixed for 5 min at 80°C and then
precipitated with alcohol. Pellets were dissolved in 20 RI of
1x hybridization buffer (80% formamide, 40 mM piperazine-
N,N'-bis)2-ethanesulfonic acid) (PIPES; pH 6.4), 400 mM
NaCl, 1 mM EDTA) and allowed to anneal at 30°C over-
night. After ethanol precipitatioh, reverse transcriptase ex-
tension reaction was carried out at 42°C for 1.5 h in a final
volume of 25 pAl containing 18 U of avian myeloblastosis
virus reverse transcriptase, 50 mM Tris-HCl (pH 8.0), 5 mM
MgCl2, 5 mM dithiothreitol, 50 mM KCI, 50 U of RNasin,
and 50 ,uM deoxynucleoside triphosphates. After RNase
digestion, phenol extraction, and ethanol precipitation, the
pellets were dissolved in 4 RI of TE and 4 ,ul of gel loading
buffer, heated at 80°C for 3 min, and loaded on a 6%
polyacrylamide sequencing gel containing 7 M urea. The
extension products were analyzed by comparison with ge-
nomic DNA sequencing reactions run in parallel. The con-
trol genomic DNA sequencing template was from a pHD1
subclone containing a 810-bp BamHI-PstI fragment in
M13mpl9.
Expression of the cDNA in E. coli. The glutathione S-trans-
ferase (GST) gene fusion system (pGEX) was used to
express the cDNA as a fusion protein (40). The vector
contains the carboxy terminus of the GST gene from Schis-
tosoma japonicum under the control of a tac promoter.
Downstream from this gene is a multiple cloning site con-
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taining BamHI, SmaI, and EcoRI restriction sites. To con-
struct an in-frame clone, cDNA was inserted into the EcoRI
site of pGEX-3X in the sense orientation to yield the
expression plasmid pGEX-UL84A. Overnight cultures of
pGEX-UL84A-transformed E. coli JM107 were diluted 1:10
with fresh medium and grown for 1.5 h at 37°C; 1 mM
isopropyl-,-D-thiogalactopyranoside (IPTG) was added to
the culture. After a further 1 to 6 h of growth, cells were
pelleted and lysed in a 0.25 volume of SDS sample buffer
(0.006 M Tris-HCl [pH 6.8], 4% SDS, 40% glycerol, 3%
dithiothreitol, 0.005% bromphenol blue). The samples were
boiled, applied to a 10% polyacrylamide gel, and subjected
to polyacrylamide gel electrophoresis (PAGE).
Inclusion bodies containing the insoluble UL84A-GST
fusion protein were prepared as described by Harlow and
Lane (12a), with modification. The induced E. coli JM107
(pGEX-UL84A) cultures were pelleted by centrifugation at
7,000 x g for 5 min, and the cell pellets were resuspended in
100 mM NaCI-1 mM EDTA-50 mM Tris-HCl (pH 8.0) to a
final concentration of 10% (vol/vol). The crude inclusion
bodies were obtained by adding lysozyme to the suspension
(1 mg/ml) and incubating the mixture at room temperature
for 20 min. Subsequently, the suspension was sonicated for
three 20-s cycles at full power with Branson model 200 cell
disruptor with a microtip and centrifuged at 5,000 x g for 10
min. The inclusion bodies collected were washed subse-
quently with ice-cold washing buffer (100 mM NaCl, 1 mM
EDTA, 50 mM Tris-HCl [pH 8.0]) with 0.1% SDS, washing
buffer with 1% Nonidet P-40, and washing buffer without
detergent. The final pellets were suspended in phosphate-
buffered saline, analyzed for purity, and used as the antigen
for antibody production.
Antibody preparation. Antiserum against the UL84A-GST
fusion protein was made by immunizing rabbits with 100 jig
of the fusion protein in the form of inclusion bodies in an
equal volume of Freund's complete adjuvant (Calbiochem
Corp.) and boosted three times with fusion proteins in an
equal volume of Freund's incomplete adjuvant (Calbiochem)
at 2-week intervals. At 12 days after the final injection,
immune rabbit serum was tested for the presence of the
specific anti-CMV antibodies by Western immunoblot anal-
ysis and immunofluorescent staining.
Western blot and indirect immunofluorescence. HEL cells
were infected with human CMV as described above. At 6,
24, and 72 h postinfection, cells were washed twice with
ice-cold phosphate-buffered saline and then lysed with SDS
sample buffer. The lysates were sheared by passage four
times through a 20-gauge needle and then boiled for 5 min.
The purified virions were also lysed with the SDS sample
buffer. Twenty micrograms of protein was loaded onto an
SDS-10% polyacrylamide gel. Control mock-infected cul-
tures were harvested with the same procedure. After elec-
trophoresis, proteins were transferred to nitrocellulose in
transfer buffer (20 mM Tris-HCl [pH 8.0], 150 mM glycine,
20% methanol) overnight at 14 V. The blot was washed four
times with washing buffer (4% dry milk in phosphate-
buffered saline) at room temperature for 25 min each time
and then probed with the UL84A-GST antiserum (diluted
1:100 in washing buffer) at room temperature for 1 h. The
antiserum was removed, and the blot was rinsed three times
with washing buffer. Detection of bound antibody-antigen
complexes was achieved by incubating the filter with 1251-
protein A (0.3 ,Ci/ml; Amersham) in 10 ml of washing buffer
at room temperature for 1 h. After drying, the filter was
exposed to X-ray film at -70°C for overnight.
For indirect immunofluorescence, CMV-infected HEL
cells on eight-well chamber slides (Nunc, Naperville, Ill.)
were harvested at the indicated times after infection. Cells
were washed with 0.01 M phosphate-buffered saline (pH 7.0)
three times and fixed with ice-chilled acetone for 15 min.
Infected and mock-infected cultures were stained first with
rabbit antiserum and subsequently with fluorescein-conju-
gated goat anti-rabbit antibody for 1 h each at 37°C.
Nucleotide sequence accession number. The GenBank ac-
cession number for the sequence reported in this communi-
cation is M81432.
RESULTS
Construction of cDNA libraries and isolation of cDNA
clones. As described in Materials and Methods, two cDNA
libraries were constructed from the total RNA and cytoplas-
mic RNA of CMV-infected HEL cells. The first six clones
with positive signals were obtained from the screening of 4 x
104 recombinant phages from the total RNA library by using
a 32P-labeled 6.5-kb BamHI fragment of CMV DNA which
contains pp65 and pp7l genes and the upstream regions of
these two genes. After further plaque purification and EcoRI
digestion, all six isolates were shown to have DNA inserts
with the same molecular size of 1.6 kb. Digestion of these
isolates with BamHI, HindIII, Sall, and PstI revealed that
all six clones contained the same restriction fragment. The
insert from one lambda gtll clone was subsequently cloned
into the EcoRI site of plasmid M13mpl9 (designated M13-
UL84A) for DNA sequence analysis.
To better understand the transcription of this cDNA, we
screened the cytoplasmic RNA library by using the 1.6-kb
cDNA probe. Fourteen clones with positive signals were
obtained from the screening of 4 x 10 recombinants. After
EcoRI digestion of the DNA isolated from positive recom-
binants, inserts of different molecular sizes (from 0.5 to 2.0
kb) were found. Four DNA inserts (2.0, 1.85, 1.7, and 1.65
kb) larger than UL84A were subsequently cloned into EcoRI
site of M13mpl9 (designated M13-UL84 and M13-UL84-1,
-2, and -3, respectively) for DNA sequence analysis.
To map the locations of these cDNAs within the CMV
genome, the radiolabeled 1.6-kb cDNA (UL84A) fragment
was hybridized to the EcoRI A fragment digested with PstI
and BamHI. The result revealed that the cDNA was located
within a 2.6-kb PstI-PstI subfragment or within a 6.5-kb
BamHI-BamHI subfragment of EcoRI-A (data not shown).
This 2.6-kb PstI subfragment was then subcloned into
M13mpl9 to determine the nucleotide sequence. This con-
struct was designated pHD1A.
Nucleotide and predicted amino acid sequences. Plasmids
M13-UL84A and pHD1A, which contain the first 1.6-kb
cDNA fragment and the 2.6-kb PstI genomic fragment,
respectively, were sequenced by the dideoxy-chain termina-
tion method. The first group of DNA sequencing data
indicated that 1.6-kb cDNA was located upstream of the
pp65 gene (Fig. 1). Comparison of M13-UL84A and pHDlA
nucleotide sequences revealed a 31-bp intron (GCGGAAC
TTACCATCTAATCCAGTTGCACCT) located within the
very 5' end of this 1.6-kb cDNA. The first exon of the 1.6-kb
cDNA contains only 8 bp. Subsequently, the sequences of
M13-UL84 and M13-UL84-1, -2, and -3 were completed. All
of the clones show no intron and coterminal 3' ends. These
results indicate that the 31-bp intron appearing in the UL84A
1.6-kb cDNA may have be an artifact generated during
cDNA synthesis. The complete nucleotide sequences of the
2.0-kb UL84 cDNA and the corresponding 2.6-kb PstI
fragment of genomic DNA are shown in Fig. 2. The genomic
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FIG. 1. Physical map of the Towne strain human CMV genome and localization of the UL84 gene. (A) Fractional length of the CMV DNA
molecule; (B) schematic representation of the CMV genome with the restriction map for EcoRI; (C) 27-kb EcoRI fragment of the HCMV
genome, designated pHD1; (D) RNA transcripts of pp65, pp7l, and UL84. The orientation of transcription is indicated by arrows.
PstI DNA fragment contains 2,600 bp, and the cDNA
sequence (shown under the genomic DNA sequence) has
1,990 bp. A single ORF capable of encoding a 587-amino-
acid peptide with a predicted molecular size of 65 kDa can be
found within this region. The first in-frame initiation codon is
found at nucleotide 439, and nucleotides surrounding the
first ATG of the ORF follow the Kozak rules for the
initiation of effective translation (20). The coding region ends
with a TAA termination codon immediately downstream of
the leucine residue at nucleotide 2200. It is followed by 143
bp of 3'-end untranslated region containing a putative poly-
adenylation signal, AATAAA, which is 124 bp from the
termination codon.
Figure 3 shows the predicted secondary peptide structure,
including hydrophilicity and hydrophobicity, antigenic do-
mains, and peptide flexibility of the UL84 peptide obtained
by computer analysis using the method of Chou and Fasman
(5). Study of the hydropathy plot reveals several distinct
hydrophilic regions located within the N-terminal half of the
peptide molecule, particularly the end and the region from
amino acid residues 150 to 185. The hydrophobic regions
were clustered at the C terminus. The antigenic domains
were centered at each terminus and also at regions with
higher flexibility. Five putative N-linked glycosylation sites
(NXT and NXS) at positions 28, 279, 354, 376, and 570 were
found. In addition, this peptide contains a high number of
leucine residues (13%). A putative leucine zipper with peri-
odic leucine repeats at every seventh position was found
between amino acids 114 and 135. Another form of periodic
leucine repeats on every eighth amino acid residues was
found in the region between amino acid residues 325 and 373.
A cluster of six threonine residues was observed at residues
53 to 58. A highly charged region with the amino acid
sequence EKKKEKEEKKEEEDEDD was found beginning
at amino acid 161.
Nucleotide sequence variations between strains Towne
and AD169 in the UL84 gene are shown in Fig. 2. Sequence
variations of approximately 2.8% (nucleotide) and 2.7%
(amino acid) were found.
Transcript analysis. Figure 4 shows the results of Northern
blot hybridization. An RNA species of 2.0 kb was first
observed as early as 2.5 h postinfection, but this message
was not seen in the RNA sample prepared in the presence of
the protein synthesis inhibitor CH, which implies that de
novo protein synthesis is required for the transcription of
UL84. When the sample was hybridized to the same amount
of RNA from 6 to 24 h postinfection, the level of this 2.0-kb
message was lower than that at 2.5 h postinfection. How-
ever, the maximal level of transcription appeared between 72
and 96 h postinfection. This bimodal expression might be
due to the second run of gene expression induced by the
infection from the newly synthesized progeny. By late times
in the infection, additional transcripts of 3.2 and 8.5 kb were
seen. To confirm these observations and monitor the amount
of RNA applied, the same blot was stripped of the UL84
cDNA probe and reprobed with a cDNA probe of the 28S
rRNA gene as an internal control. As shown in Fig. 4b, the
amounts of RNA samples loaded from mock-infected cells,
CH-treated infected cells harvested at 2.5 h postinfection,
and CMV-infected culture harvested at various times after
infection are in a very narrow range. Results from these
studies suggest that the UL84 gene is a very early gene
which can be detected as early as 2.5 h after virus infection.
The IE gene products are needed for the transactivation of
UL84 gene expression.
To determine the location and sequence of the transcrip-
tion initiation site, primer extension experiments were per-
formed. Total RNAs were hybridized with a 32P-end-labeled
oligonucleotide primer (20-mer) complementary to the ge-
nomic DNA sequences from bases 728 to 747 (Fig. 2). The
result revealed that the RNA start site was located around
302 bp upstream from the oligonucleotide primer, at base 426
(Fig. 5). A putative TATA box (TATTTAA) was found 24
bases upstream from the cap site. Several inverted repeat
sequences, designated IR1, IR2, IR3, and IR4 (Fig. 2), also
were found at the upstream region from nucleotides 233 to
334. No typical CAAT box was found around -75. How-
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FIG. 2. Comparison of the nucleotide and deduced amino acid sequences of the UL84 genes of strains Towne and AD169. A potential
TATA consensus sequence and a CAAT box are boxed; the transcription initiation site identified by primer extension is indicated by an arrow
plus CAP; several inverted repeat sequences (IR1, -2, -3, and -4) are shown; a cAMP response element consensus sequence (TGACGTT) is
underlined; the translation initiation site and the polyadenylation signal sequence are also underlined; and the leucine repeats are indicated
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further upstream from the cap site of the inverted repeats at
-311 to -319.
Expression of UL84A cDNA as a fusion protein in E. coli.
The expression plasmid pGEX-UL84A was constructed by
inserting a UL84 cDNA EcoRI fragment into the EcoRI
cloning site of pGEX-3X. The vector pGEX-3X contains a
26-kDa GST gene derived from the parasitic helminth S.
japonicum and is under the control of a tac promoter. After
inspection of the cDNA sequences, we found that the 1.6-kb
UL84A cDNA can be directly inserted into the EcoRI site of
pGEX-3X to express it as an in-frame fusion protein with the
31-bp intron at the 5' end. The reading frame and coding
sequence were identical to those of the full-length 2.0-kb
cDNA UL84 after amino acid 115. Therefore, a C-terminal
fusion protein with a molecular size of 80 kDa (26 kDa of
GST and 54 kDa of UL84) was successfully overexpressed.
Figure 6 showed the time course of the expression of this
fusion protein in E. coli after IPTG induction (an 80-kDa
Coomassie band is indicated by an arrow). To determine
whether the expressed fusion protein was aggregated in
inclusion bodies, the cells were lysed with lysozyme and
then subjected to several differential low-speed centrifuga-
tions to purify inclusion bodies. The inclusion body pellet
and the cytoplasmic supernatant were analyzed by SDS-
PAGE. Data from this experiment revealed that more than
90% of the fusion protein synthesized was present as inclu-
sion bodies.
Figure 7a shows that a 65-kDa protein could be detected in
infected-cell extracts harvested between 6 to 72 h postinfec-
tion by Western blot analysis using the rabbit antiserum
against the UL84A-GST fusion protein. This protein was not
present in mock-infected cell extracts. An additional protein
with molecular size of 90 kDa was seen in the infected-cell
extracts at 72 h postinfection. Figure 7b shows the Western
blot analysis of purified virus. UL84 protein was not de-
tected from at least two virion preparations, which indicated
that the UL84 gene product is not a structural protein.
Figure 8 shows the synthesis and location of UL84 protein
at various times after infection, as determined by indirect
immunofluorescence. Perinuclear localization of this protein
was observed at 6 to 7 h after virus infection. By 24 h,
nuclear fluorescence could be demonstrated. Heavy but
specific fluorescent staining was exhibited at both nuclear
and cytoplasmic regions of CMV-infected cells at later
stages of infection (72 h postinfection).
DISCUSSION
The goal of this study was to identify early or late
transcripts of human CMV genes in an attempt to better
understand the control of viral gene expression in CMV-
infected cells. Recently, a number of early and late genes
have been mapped (3, 6, 7, 12, 14-16, 21-31, 36, 37, 41),
allowing for specific analysis of their regulated expression.
The results suggested that various CMV early or late genes
are regulated differently (2, 9, 18, 19, 22, 38, 42). In this
report, we describe the complete nucleotide sequences,
RNA mapping, and expression of a human CMV early
transcript, UL84.
Sequence analysis of UL84 cDNA revealed an ORF
capable of encoding a 65-kDa peptide. According to the
analysis of the protein-coding content of the sequence of
human CMV strain AD169 described by Chee et al. (4), a
UL84 ORF encoding a 65-kDa peptide and located at the
immediate upstream region of the UL83 or pp65 gene was
predicted. Because of the identities between our full-length
cDNA and the UL84 ORF predicted by Chee et al. with
respect to peptide size and the position of the translation
initiation codon, we use the same name, UL84, to designate
the gene for this 2.0-kb cDNA. The cDNAs UL84-1, -2, and
-3 were non-full-length cDNAs, as judged by the features of
3' ends coterminal with that of the 2.0-kb cDNA. However,
the first cDNA, UL84A, isolated from a total RNA library,
contains an 31-bp intron. An ORF encoding a 364-amino-
acid, 41-kDa peptide could be deduced from the exon 2
region of the UL84A 1.6-kb cDNA sequence. This 41-kDa
peptide has a carboxy end coterminal with that of the peptide
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FIG. 3. Two-dimensional structure of the UL84 peptide obtained by Chou-Fasman computer analyses. The amino and carboxy termini are
indicated. KD, Kyte-Doolittle.
sequences of splicing donor and acceptor were not found at
the 3' end of exon 1 and 5' end of exon 2 of the UL84A
sequence. This implies that 31-bp splicing within the 1.6-kb
cDNA might be an artifact. Western blot analysis using a
rabbit anti-UL84A fusion protein further confirmed this
observation; a protein of 41-kDa could not be detected in the
infected-cell extract.
UL84, a member of the first subclass of human CMV early
genes, is transcribed into a 2.0-kb mRNA which appears as
early as 2.5 h postinfection. Primer extension analysis of this
mRNA revealed a putative transcription initiation site within
a region about 14 nucleotides upstream of the first ATG of
the UL84 ORF, which was only one base further than that of
the UL84 cDNA start site. This analysis suggested that the
UL84 cDNA was short one nucleotide at the 5' end. The
mRNA size estimated from the primer extension and the
sequence of the UL84 cDNA matches perfectly the size of
the message detected from Northern hybridization analysis.
To investigate whether a putative functional promoter is
located within the upstream region of the cap site of the
UL84 gene, we have analyzed the sequences from the cap
site to the 5'-end PstI site. Three structural features were
observed: (i) a TATTTAA sequence located 23 nucleotides
upstream of the cap site that might represent a TATA motif,
(ii) several inverted repeat sequences located within the
upstream region of the putative TATA box (IR1 [AGC
CGCGC], IR2 [GCCGCGCG], IR3 [CACGTGTC], and IR4
[CGTGGATGACCTTCATCCGCG]), and (iii) the absence
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FIG. 4. Northern blot analysis of the UL84 transcript. Total
RNA was prepared from mock-infected (lane A) and virus-infected
(2.5 h plus CH, 2.5 h, 6 h, 24 h, 72 h, and 96 h postinfection; lanes
B to H, respectively) HEL cells by the guanidinium isothiocyanate-
cesium chloride method. Eight micrograms of total RNA was
subjected to electrophoresis through a 1.2% agarose gel containing
6% formaldehyde and then transferred to nitrocellulose. The result-
ing filter was hybridized with 32P-labeled UL84A cDNA (a) and with
32P-labeled cDNA of 28S rRNA (b). Locations of the 2.0-, 3.2-, and
9.0-kb UL84 transcripts and of 28S rRNA are indicated by arrows.
The RNA ladder on the left is shown in kilobases.
of a typical CAAT box around -75 from the cap site;
instead, there is a classic CAAT box sequence (GGCCAA
TCT) located upstream of the inverted repeats at -311 to
-319 from the cap site. These inverted repeat sequences
may be involved in the regulation of expression of the UL84
gene, but computer analysis of a number of other CMV early











FIG. 5. Primer extension analysis. A synthetic 20-base oligonu-
cleotide, 5'-TGCACCCGAGGCTGACGGAT-3', was end labeled
by T4 polynucleotide kinase and [32P]ATP. The end-labeled primer
was annealed to 6 ,ug of total RNA from mock- and virus-infected
HEL cells at the indicated times. Avian myeloblastosis virus reverse
transcriptase was used for primer extension. The corresponding
complementary nucleotides were sequenced in parallel to allow
direct reading of the coding sequence. The transcription initiation
site (asterisk) predicted from the primer extension is shown at the
left.
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FIG. 6. Expression of UL84A cDNA in E. coli JM107. Overnight
cultures of JM107 (B) and of JM107 transformed with expression
vector pGEX-3X (lane C) and recombinant vector pGEX-UL84A
(lanes D to H) were diluted 1:10 in YT medium, grown for 1 h, and
then induced with IPTG. Samples were harvested at 0, 0.5, 1, 2, and
4 h (lanes D to H, respectively), subjected to SDS-PAGE analysis,
and stained with Coomassie blue. Lane A indicates protein molec-
ular sizes in kilodaltons. Arrows show the positions of the expressed
fusion protein (80 kDa) and GST (26 kDa).
promoters and cellular promoters did not reveal any signif-
icant homology to these inverted repeats. It is possible that
only a few nucleotides are needed for specific interactions
between DNA and proteins for promoter activation. To
verify the existence of promoter activity within this region,
we constructed a chloramphenicol acetyltransferase (CAT)
expression plasmid by fusing a PstI-SphI fragment, contain-
ing the upstream region of the UL84 gene, to the CAT
indicator plasmid pKK232-8. Significant promoter activity
was detected from this sequence after CMV induction (12b).
Prepared UL84 antiserum and immunofluorescence stain-













FIG. 7. Immunoblot of the purified extracellular human CMV
virions and the proteins extracted from human CMV-infected cells.
After SDS-PAGE separation, the proteins were transferred to
nitrocellulose and probed with rabbit antiserum against the UL84A-
GST fusion protein. 125I-protein A was used to monitor the reacted
antibody. (a) Proteins extracted from human CMV-infected (72, 24,
and 6 h postinfection [lanes A to C, respectively]) and mock-infected
(lane D) HEL cells; (b) proteins extracted from human CMV-
infected cells harvested at 24 h postinfection (lane A), from purified
virions (lane B), and from mock-infected cells (lane C). Positions of
molecular weight markers are shown at the left in kilodaltons; the
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FIG. 8. Indirect immunofluorescence test. The mock-infected (a) and human CMV-infected (6, 24, 48, and 72 h postinfection [A to D,
respectively]) HEL cells were reacted with the first rabbit antibody and stained with fluorescein-conjugated goat anti-rabbit antibody.
ing detected functional virus-specific protein in CMV-in-
fected HEL cells. The 65-kDa protein detected in infected-
cell extracts harvested between 6 to 72 h postinfection and
the 90 kDa protein observed at later stages of virus infection
share some common antigenic epitopes, as reflected by their
reactivity to UL84 antiserum. It is possible that there is
extensive posttranslational modification of this protein in
late stages of CMV infection, or this 90-kDa peptide may
reflect the translation product of the additional transcripts.
Studies of the peptide structure and computer analysis of the
amino acid sequence revealed the presence of five potential
N-linked glycosylation sites (Asn-X-Ser and Asn-X-Thr)
within the ORF. In addition, many other 0-linked glycosy-
lations may occur within this peptide because the serine and
threonine residues make up 13% of the total amino acid
composition, and they are the acceptor sites for 0-linked
oligosaccharides These two amino acid residues are heavily
distributed at both N- and C-terminal ends of this peptide.
The leucine zipper found in the region between amino
acids 114 and 135 at the N-terminal half of molecule implies
that this peptide may be involved in downstream gene
regulation via dimerization, with itself or other molecules,
and DNA binding. In addition, another periodic array of
leucine on every eighth amino acid was found in the region
between amino acids 325 and 349. The arrangement of this
periodic leucine repeat is L(X7)L(X7)L(X7)L(X7)P(X7)
L(X7)L(X7). This unique class of leucine repeat might be
able to form a leucine coil to interact with other macromol-
ecules. The significance of this leucine repeat has not been
analyzed. Two additional unique features of the UL84 pep-
tide were observed: a six-threonine cluster at positions 53 to
58 and the highly charged amino acid cluster at positions 161
to 177. The function of the six-threonine cluster is not clear.
Whether the highly charged amino acid cluster associates
with nuclear localization requires further study.
UL84 is a very early gene whose biological function is not
clear. The translated protein was shown to be very stable
and was not found associated with purified virions. It could,
therefore, be a regulatory protein or an enzyme which
performs its function at very early as well as late stages.
Studies of the biochemical characteristics of the protein
encoded by UL84 and identification of the essential cis-
acting elements controlling UL84 gene expression are under
way.
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